Krestin (PSK)

https://doi.org/10.1016/0305-7372(84)90005-7Get rights and content

Abstract

A polysaccharide preparation isolated from Coriolus versicolor (Fr.) Quél. of Basidiomycetes (PSK) predominantly consists of glucan and approximately 25% tightly bound protein. PSK was effective against various allogeneic and syngeneic animal tumors and has been given orally to cancer patients.

Various suppressed or enhanced immune responses of tumor-bearing animals were restored to normal levels by the administration of PSK in the tumor models tested.

The killer T cell activity was augmented in tumor-bearing mice by intraperitoneal or oral administration of PSK, and there was correlation between the PSK associated antitumor effect and the killer T cell activity.

It was found that PSK competed with immunosuppressive substances isolated from tumor-bearing mice and that the intestinal immune system appeared to be modulated by oral administration of PSK.

After oral administration of 14C- or 35S-labeled PSK to normal rats, it was found that small or large molecular substances appeared in the serum depending on the time elapsed after administration, an indication that large molecular size products were from the digestive tract.

References (132)

  • M.A. Chirigos et al.

    Polysaccharide and related substances II

  • S. Muto et al.

    Structure and antitumor effect of PSK (KRESTIN): Mechanistic aspects of the antitumor activity

  • S. Abe et al.

    Correlation of differences in antigenicity of four 3-methyl-cholanthrene-induced tumors in syngeneic mice with the susceptibility of tumors to an immunopotentiator, PS-K

    Gann

    (1978)
  • J. Akiyama et al.

    Immunochemotherapy of transplanted KMT-17 tumor in WKA rats by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from Basidiomycetes

    Cancer Res.

    (1977)
  • T. Ando et al.

    The in vitro effects of PS-K on the growth of mouse Ehrlich ascites tumor cells

    Clin. Rep.

    (1975)
  • T. Ando et al.

    Effect of PSK on macrophage chemotaxis

  • T. Ando et al.

    Effect of PSK on macrophage functions in mice bearing X5563 tumor

  • T. Ando et al.

    Effect of PSK on macrophage function in tumor-bearing mice

  • T. Ando et al.

    Effect of PSK on immune response to sheep erythrocytes in syngeneic transplantable tumor-bearing mice

  • T. Ando et al.

    Effect of PSK against Pseudomonas aeruginosa infection in tumor-bearing mice

  • T. Ando et al.

    Protective effect of PSK against experimental candidiasis in mice under liable condition to infection

  • W.T. Bradner et al.

    Stimulation of host defense against experimental cancer I. Zymosan and sarcoma 180 in mice

    Cancer Res.

    (1958)
  • W.T. Bradner et al.

    Stimulation of host defense against experimental cancer II. Temporal and reversal studies of the Zymosan effect

    Cancer Res.

    (1959)
  • G. Chihara et al.

    Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing

    Nature

    (1969)
  • K. Ebihara et al.

    The effect of immunopotentiators on the resistive activity of mouse infection by cytomegalovirus

  • T. Ebina

    New interferon inducers

  • M.J. Enrke et al.

    The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens

    Int. J. Immunopharmacol.

    (1983)
  • H. Fujita

    Distribution of immunotherapeutic agent and its mechanism in the body

    Pharma Med.

    (1983)
  • H. Fujita et al.

    Study of PSK on the absorption, tissue distribution and metabolism and the effect to drug-metabolizing enzyme, P-450

  • K. Fujita et al.

    Effect of Krestin on bladder tumor induction in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine

    Acta Urol. Jpn.

    (1979)
  • H. Fujiwara et al.

    Immunotherapeutic agent XI PSK

  • Y. Fukuo et al.

    Effect of immunoregulator on LDL receptor by PSK

  • K. Hasegawa et al.

    Study for the prevention of carcinogenesis in rabbit lung cancer experimentally induced by MNUcomparison of PSK with N-CWS

    Lung Cancer

    (1981)
  • T. Hattori et al.

    Postoperative long-term adjuvant immunochemotherapy with mitomycin C, PSK, FT-207, and Levamisole in gastric cancer patients

  • H. Hiraga et al.

    Immunotherapy of sarcoidosis

  • A. Hirasawa

    Seroconversion of HBe antigen in chronic hepatitis

  • S. Hirase et al.

    Structural studies on the anti-tumor active polysaccharides from Coriolus versicolor (Basidiomycetes). II. Structures of β-D-glucan moieties of fractionated polysaccharides

    Yakugaku Zasshi

    (1976)
  • M. Hosokawa et al.

    An attempt of immunochemotherapy with PS-K and cyclophosphamide on MCA-induced autochthonous tumor in C57BL/6 mice

  • S. Ichikawa et al.

    Effect of PSK on experimental hepatoma

    Jpn. J. Gastroenterol.

    (1983)
  • T. Ichikawa et al.

    Inhibitory effect of a few factors on the tumorigenesis in rat esophagus, large intestine and mammary gland

  • H. Iida

    Intestinal absorption of Botulinal toxin

    Modern Media

    (1968)
  • T. Ikekawa et al.

    Antitumor action of some Basidiomycetes, especially Phellinus linteus

    Gann

    (1968)
  • T. Ikekawa et al.

    Antitumor activity of aqueous extracts of edible mushrooms

    Cancer Res.

    (1969)
  • Y. Imai et al.

    Effect of immunopotentiator on NZB mice

  • S. Imura

    The effect of Krestin (PSK) on the various connective tissue diseases

  • K. Kanazawa et al.

    Inhibitory effects of OK-432 and PSK on cell growth of in vitro human choriocarcinoma cell lines GCH-1 and GCH-2

    Jpn. J. Cancer Chemother.

    (1983)
  • S. Kaneko et al.

    Experimental study of immunochemotherapy of brain tumors

    Neurol. Med. Cir.

    (1980)
  • T. Kano et al.

    Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach

    Jpn. J. Surg.

    (1981)
  • T. Kasamatsu

    The radiation sensitizing effect of PSK in the treatment for the cervical cancer patients

  • T. Kataoka et al.

    Enhanced induction of immune resistance by concanavalin A-bound L 1210 vaccine and an immunopotentiator prepared from Coriolos versicolor

    Cancer Res.

    (1977)
  • F. Kato et al.

    Immunotherapy in herpetic stromal keratitis

  • F. Kato et al.

    Studies on immunotherapy for the experimental herpes simplex keratitis

    Acta Soc. Ophthalmol. Jpn.

    (1980)
  • H. Kato et al.

    Effect of BCG, OK-432 (Picibanil), PS-K (Krestin), and Levamisole on guinea pig complement system

    Clin. Immunol.

    (1981)
  • T. Kawana

    Therapy for genital herpes

    Clin. Gynecol. Obstetr.

    (1981)
  • K. Kimura et al.

    Immunotherapy in patients with glomerulonephritis

    Clin. Immunol.

    (1980)
  • H. Kitani et al.

    Effect of an immunomodulator PSK on the production of interferon in tumor-bearing mice

    J. Natl. Def. Med. Coll.

    (1981)
  • M. Kitasato

    Increase of antitumor activity in experimentally induced tumor-bearing animals by simultaneous administration of two immunopotentiating agents

    J. Jpn. Soc. Cancer Ther.

    (1982)
  • M. Kondo et al.

    Activation of the complement by immunostimulants, BCG, OK-432 (Picibanil), and PS-K (Krestin) in vitro

    Gann

    (1978)
  • M. Kondo et al.

    Evaluation of an antitumor activity of a protein-bound polysaccharide PS-K (KRESTIN)

  • K. Matsunaga et al.

    Effect of PS-K on immune response (5) Depressed resistance against Listeria monocytogenes infection in tumor-bearing mice and its restoration by PS-K

  • Cited by (270)

    • Structural characteristics of a red ginseng acidic polysaccharide rhamnogalacturonan I with immunostimulating activity from red ginseng

      2020, Journal of Ginseng Research
      Citation Excerpt :

      Optical density of the supernatant was measured at 412 nm. Polysaccharide K (PSK) from Coriolus versicolor and CVT-E002 (sold commercially as Cold-FX, Valeant Pharmaceuticals International, Canada) from Panax quinquefolium were used positive controls [22,23]. The anticomplementary activity has been expressed as follows:Total hemolytic complement (TCH50) (%) = TCH50 (control) − TCH50 (treated with sample)/TCH50 (control)

    • Fungal polysaccharides

      2020, Advances in Pharmacology
    View all citing articles on Scopus
    View full text